Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q34624122

about

Genomic diversity of colorectal cancer: Changing landscape and emerging targets Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Lung cancer biomarkers, targeted therapies and clinical assays Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis Personalized treatment for advanced colorectal cancer: KRAS and beyond Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis Molecularly targeted drugs for metastatic colorectal cancer The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance Multi-modality treatment of colorectal liver metastases Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement Management of locally advanced and metastatic colon cancer in elderly patients Epidermal growth factor receptor inhibitors: coming of age Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care Role of targeted therapy in metastatic colorectal cancer Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence RAS and BRAF in metastatic colorectal cancer management Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status Patient-reported outcomes in randomised controlled trials of colorectal cancer: an analysis determining the availability of robust data to inform clinical decision-making Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment Second-line systemic therapy for metastatic colorectal cancer.The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data Where now for anti-EGF receptor therapies in colorectal cancer?Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS.Patient considerations in metastatic colorectal cancer - role of panitumumab.Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC).Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.

P2860

Q26739052-8DA83B78-6466-44B4-BC1C-8019008D0953 Q26748924-7EB78A1B-ABDA-42C3-A13F-23BF2FCEBE4F Q26766535-16E630FD-97AA-4B7B-BFA1-4CD5EDA38CCB Q26769958-BE19E4E4-7435-4DE2-82A8-C446C1F45C9B Q26775396-6290FC3F-2D7F-4D2F-8BED-148414E74B5C Q26775522-130E6C3F-F68E-4080-9EC3-009764555FD5 Q26777704-147BA69C-87E1-4362-822D-5A15D725394A Q26822817-76F46489-E349-48B3-A4C7-55CE73D58A10 Q26827474-155CF14F-1798-4768-87DF-D1D9064E581C Q26828735-891BD013-0451-4320-BC91-4E8374281DEF Q26858892-09189BF4-D099-4B1E-8A52-45110C14EB4F Q26866517-1E033127-977F-422E-AFC4-938B7833D27C Q27006832-4CF0C670-1EAC-4BDB-83A6-A2469527A2AC Q27015224-1C197476-4F2A-43F6-9D83-D90121F3E77C Q27020973-C6A24A92-47C4-4B41-966E-9AD1FE9F83BC Q27026129-EB49B3CC-EEFB-4F96-A065-C0C0DD9A4ADB Q27030769-2466FE60-0B15-40B5-8FBA-0F879E364CC4 Q27851708-E9726BB9-ADF6-40BC-8F3D-ACC3F24EB96B Q27852988-649C3D43-9861-4569-ADCB-7094C7C78A43 Q28066460-2E6D4034-6D37-407F-AECA-64AAEF162F5B Q28068817-CE87C00E-294A-4496-87CF-AE3612A898E5 Q28071772-A74AAC21-BD65-4F53-9E2F-A4747DC25EC1 Q28074175-48060F53-147A-42D6-82B3-656D799F65D8 Q28076490-771F51BD-D6C3-4977-825D-156D4355D457 Q28082816-7E4B806E-4176-4733-AB91-A4CE48800F94 Q28087212-DFC369D8-4C30-415A-B940-DB69D8BBD0D2 Q28087333-6CB2F33F-2A41-4AAB-96E5-BCD79354FB7D Q28543278-E7AD4901-1DF0-4A41-B00D-AF94DC8DC1AA Q28741021-584E5CEE-41A7-4565-865C-4DE5E35FB99B Q30238760-3D9B6AD5-9E66-4939-AD82-53EEF2A5A151 Q30240061-5A69034D-A7A2-4D24-92F2-D3223453B222 Q30862367-F5133F36-4977-4FAD-80BF-66EDB537A06D Q31038305-F70979D1-54A0-453B-A746-96DF167BE737 Q31048123-3A7C9A4A-2F66-4AE2-B662-962E5F14A8CE Q33411061-FA89793A-9B36-4B8F-8945-1E406C5FBA0D Q33440505-7B56DC84-4AC0-4A99-AE4B-015139A31B9D Q33563293-2FFDD065-37ED-4336-932A-2BED5EEA8E15 Q33564335-A0669971-7C64-4063-BA96-40967552E1FE Q33624491-DA765ABD-5B1A-470A-9ADC-5AA385C3F88E Q33683680-30416D15-8341-4EB3-BBEE-0BDA53A51762

P2860

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q34624122

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Randomized phase III study of ...... metastatic colorectal cancer.

@ast

Randomized phase III study of ...... metastatic colorectal cancer.

@en

Randomized phase III study of ...... metastatic colorectal cancer.

@nl

type

label

Randomized phase III study of ...... metastatic colorectal cancer.

@ast

Randomized phase III study of ...... metastatic colorectal cancer.

@en

Randomized phase III study of ...... metastatic colorectal cancer.

@nl

prefLabel

Randomized phase III study of ...... metastatic colorectal cancer.

@ast

Randomized phase III study of ...... metastatic colorectal cancer.

@en

Randomized phase III study of ...... metastatic colorectal cancer.

@nl

P1433

Q34624122-B573EC37-E6A8-4B3F-A178-E67D4348C579

P1476

Q34624122-0A828173-4BF4-4C52-ACEC-B71AD24FEAAE

P2093

Q34624122-0FA3B050-D7B6-4F03-84B1-4D0FF4DC4CBB

Q34624122-1F2320BF-A52D-45C1-9292-E90C6F37C3A8

Q34624122-4FAC3FA0-F6B0-43C9-AEA5-4D7F4D63716C

Q34624122-5ADE8DE7-058A-47FF-B14D-BA98AEBB388C

Q34624122-64B87AF4-8A08-433A-AE05-F96FAF8EA16A

Q34624122-725CF69E-75FF-4498-9F01-1FBE9ED53F3E

Q34624122-75EFD184-3232-4AFF-B809-1A16B4ACFEF1

Q34624122-7C36A7A0-A9F3-44A7-9BE8-6C682EA2CB4E

Q34624122-8433E2E2-3B40-48C7-8E1B-4D5695B90C12

Q34624122-980F35F1-4691-4601-B85B-DC6142BB6C42

P304

Q34624122-E77CAE6B-9243-4EA1-8BBE-301EAD4185D3

P31

Q34624122-4F25634C-B838-4130-BB10-F102F1A58DB1

P356

Q34624122-B7EE4FC8-5ACD-4E1A-93F6-E3627918F3A2

P407

Q34624122-9E38D8AB-6A68-4564-ADE0-2976199A96A3

P433

Q34624122-E9323093-11B3-4ED1-AEAC-C06B2E952D7A

P478

Q34624122-25CC57EC-66A6-436E-A268-1F480BC53AA6

P50

Q34624122-2D1DB7FA-CEA4-4087-A3F3-D2640787A2C1

Q34624122-DA8E1CB0-0AB2-484D-95D7-AD9921D368F7

Q34624122-EE25A9F2-3C36-43E1-AED8-77A3D6E65245

P577

Q34624122-0BDF400E-77E9-4B92-9616-94442FDD248C

P698

Q34624122-206C0332-629C-40A7-A5A0-37E0AEA10A52

P921

Q34624122-CF563687-9FEC-440D-9C8B-DFECF2A026E8

Q34624122-DD018D74-A682-4F82-A1C3-75D6EFDC8A12

P356

JCO.2009.27.6055

P1433

Journal of Clinical Oncology

P1476

Randomized phase III study of ...... h metastatic colorectal cancer

@en

P2093

Alan Rong

http://www.w3.org/2001/XMLSchema#string

Alberto F Sobrero

http://www.w3.org/2001/XMLSchema#string

Andrew H Strickland

http://www.w3.org/2001/XMLSchema#string

Andrés Cervantes

http://www.w3.org/2001/XMLSchema#string

Cornelis J A Punt

http://www.w3.org/2001/XMLSchema#string

Emily Chan

http://www.w3.org/2001/XMLSchema#string

Eric Van Cutsem

http://www.w3.org/2001/XMLSchema#string

Florian Lordick

http://www.w3.org/2001/XMLSchema#string

Gregory Wilson

http://www.w3.org/2001/XMLSchema#string

Jennifer Gansert

http://www.w3.org/2001/XMLSchema#string

P304

4706-4713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.6055

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20921462

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer